Sight Sciences

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. It also develops pharmaceuticals, drug delivery systems, and diagnostics for the treatment of ophthalmic conditions. The firm's products include viscosurgical system and trabeculotomy instruments. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sight Sciences reports stellar Q4 earnings, eyes sustainable growth

Sight Sciences delivered strong revenue growth in Q4 2022, driven by successful product offerings and market expansion efforts. While facing increased operating expenses and margin challenges, the company remains optimistic about achieving cash flow breakeven by 2025 and sustaining growth through innovative technologies and market strategies.

Sight Sciences excels in Q1 earnings, eyes growth opportunities

Sight Sciences' Q1 2023 performance reflects strong revenue growth, effective cost management, and a clear path towards achieving financial targets.
The company's leadership reinforcement, strategic focus on cash flow, and discussions on market trends position it well for future success.
While facing challenges in reimbursement changes and operational efficiency, Sight Sciences is poised to leverage opportunities for innovation and growth.

Sight Sciences excels in Q2 with record revenue and clinical validation

Sight Sciences demonstrated strong financial performance, highlighted by revenue growth and operational improvements. While facing challenges related to potential impacts on product sales and reimbursement discussions, the company remains optimistic about the growth prospects of its innovative technologies and reaffirmed its annual revenue guidance.

Sight Sciences reports Q3 revenue growth amidst operational improvements

Sight Sciences delivered solid financial performance in Q3, with revenue growth, margin improvement, and cost-saving measures
While facing challenges related to market access and revenue uncertainties, the company's strengths in innovation and efficiency position it well for future growth
Strategic opportunities in product development, market expansion, and operational optimization can drive sustained success and value creation for stakeholders

Sight Sciences posts successful Q4 results amidst revenue challenges

Sight Sciences reported strong financial performance in Q4 2023, with revenue growth, improved margins, and reduced expenses.
The company faces challenges in revenue decline for Q4, optimizing commercial strategies, and navigating reimbursement landscapes.
Opportunities lie in market expansion, revenue growth, reimbursement wins, and shifting treatment paradigms towards minimally invasive interventions.
Overall, Sight Sciences is well-positioned with a focus on innovation, clinical efficacy, and commercial strategies for 2024 opportunities.

Sight Sciences reports record Q1 revenue and eyes sustained growth

Sight Sciences posted strong financials with record revenue and improved cash usage.
Focused on driving growth in Surgical Glaucoma and addressing challenges in Dry Eye market.
Opportunities lie in market expansion, technology adoption, and sustained growth.
Company optimistic about achieving double-digit growth in the coming quarters.

Sight Sciences reports strong Q2 results, eyes growth opportunities ahead

Sight Sciences demonstrated robust financial and operational performance in Q2 2024, driven by revenue growth and improved cash management.
Strategic initiatives in surgeon training, product differentiation, and pricing reflect the company's focus on market expansion and value realization.
While facing challenges in revenue outlook and market dynamics, Sight Sciences remains poised to capitalize on growth opportunities in both Surgical Glaucoma and Dry Eye segments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients' lives, today reported financial results for the quarter and year ended December 31, 2021.

Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject® in lowering intraocular pressure (IOP) as a standalone treatment option without concomitant cataract surgery. Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject® in lowering intraocular pressure (IOP) as a standalone treatment option without concomitant cataract surgery.

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

Legislative and health policy expert brings extensive private and public sector experience Legislative and health policy expert brings extensive private and public sector experience

Sight Sciences Announces Appointment of Brenda Becker to Board of Directors

MENLO PARK, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced it will report financial results for the quarter and year ended December 31, 2021, after the market close on Thursday, March 24, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

MENLO PARK, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients' lives, today announced plans to participate in the upcoming Citi Virtual Healthcare Conference.

Sight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference

Educational campaign aims to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma Educational campaign aims to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma

Sight Sciences Launches “Don't Wait for Too Late” Awareness Campaign for Glaucoma

Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Sight Sciences (SGHT)

Sight Sciences has seen its shares been cut in half compared to the first price after the IPO this past summer. This pullback came while top line sales developments have been solid and another FDA clearance has rolled in.

Sight Sciences: Appeal Is Visually Increasing

MENLO PARK, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients' lives, today announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2021.

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results

The FDA has cleared Sight Sciences Inc's (NASDAQ: SGHT) TearCare System for meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED).  The indication clears TearCare for applying localized heat therapy in adult patients with evaporative DED due to MGD when used with the manual expression of the meibomian glands.

FDA Approves Sight Sciences' TearCare System For Common Eye Condition

MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients' lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference.

Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference

Sight Sciences Inc. (SGHT) CEO Paul Badawi on Q3 2021 Results - Earnings Call Transcript

The FDA has signed off Sight Sciences Inc's (NASDAQ: SGHT) clinical study to assess investigational higher volume OMNI device to perform canal viscodilation alone to lower intraocular pressure (IOP) in adults with primary open-angle glaucoma (POAG). The PRECISION trial is designed as a three-armed randomized controlled trial with patients receiving micro-invasive glaucoma surgery (MIGS) interventions in conjunction with cataract surgery (n=459).

FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure

MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients' lives, today reported financial results for the quarter ended September 30, 2021.

Sight Sciences Reports Third Quarter 2021 Financial Results

As the pioneer of ab interno canaloplasty, Sight Sciences is executing this IDE trial to seek FDA clearance for canal viscodilation alone as a MIGS procedure for adults with POAG As the pioneer of ab interno canaloplasty, Sight Sciences is executing this IDE trial to seek FDA clearance for canal viscodilation alone as a MIGS procedure for adults with POAG

Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)

The average of price targets set by Wall Street analysts indicates a potential upside of 72.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 73% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021

The mean of analysts' price targets for Sight Sciences, Inc. (SGHT) points to a 67.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 68% Upside in Sight Sciences, Inc. (SGHT): Can the Stock Really Move This High?

On Thursday, Sight Sciences Inc. (NASDAQ:SGHT) shares rallied more than 12% after reporting positive TearCare data. SGHT is exploring how TearCare could be used for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction.

Sight Sciences stock prediction as shares spike 12% on positive TearCare data

Clinical trial data being used to seek expanded indication from the FDA Clinical trial data being used to seek expanded indication from the FDA

Sight Sciences Announces TearCare® Clinical Data Published in Cornea

Sight Sciences Seeks Injunction Related to Hydrus® Microstent's Infringement Sight Sciences Seeks Injunction Related to Hydrus® Microstent's Infringement

Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced plans to participate in the upcoming virtual Morgan Stanley Global Healthcare Conference.

Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

Sight Sciences, Inc. (SGHT) CEO Paul Badawi on Q2 2021 Results - Earnings Call Transcript

MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursday, August 12, 2021. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

New safety and efficacy data from both retrospective and prospective studies of the OMNI Surgical System and a prospective study of the TearCare System to be presented New safety and efficacy data from both retrospective and prospective studies of the OMNI Surgical System and a prospective study of the TearCare System to be presented

News for Sight Sciences Stock (SGHT)